Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 455 results for anxiety

  1. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.

  2. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

  3. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    body positioning session)• patient reported outcomes including dyspnoea, anxiety, delirium, pain, discomfort, breathlessness, impact on...

  4. LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)

    NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home

  5. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

  6. Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  7. Long-acting reversible contraception (CG30)

    This guideline covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices.

  8. Obesity prevention (CG43)

    This guideline covers preventing children, young people and adults becoming overweight or obese. It outlines how the NHS, local authorities, early years’ settings, schools and workplaces can increase physical activity levels and make dietary improvements among their target populations.

  9. The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)

    NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy

  10. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  11. Developmental follow-up of children and young people born preterm (NG72)

    This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.

  12. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  13. Depression in children and young people: identification and management (NG134)

    This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.

  14. Decision-to-birth interval (category 1 urgency): What factors influence the decision-to-birth interval when there is a category 1 level of urgency for caesarean birth?

    This should be done as efficiently and effectively as possible, minimising anxiety and ensuring the safety of the mother and her baby....